Stockscreener 앱 받기
28.01
5.54%
1.47
시간 외 거래:
28.10
0.09
+0.32%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
What drives Summit Therapeutics Inc. stock priceTremendous growth potential - Autocar Professional
What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - AOL.com
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
how summit therapeutics inc. stock performs during market volatilityAnalyst Grade Signals - Newser
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Inc (SMMT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What makes Summit Therapeutics Inc. stock price move sharplyFree Predictions - Newser
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Why Summit Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
BPAS - FinancialContent
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
Where are the Opportunities in (SMMT) - news.stocktradersdaily.com
10 Stocks Going Wild - Insider Monkey
0.51%
0.25%
자본화:
|
볼륨(24시간):